

**PREVALENCE AND RISK FACTORS FOR PULMONARY MYCOBACTERIOSIS IN LAGOS, NIGERIA**

**Abstract**

**Background:** Pulmonary mycobacteriosis has been documented in HIV-infected, diabetics, asthmatics, smokers and alcoholics and its progression and severity are affected by these risk factors. Inappropriate diagnosis of mycobacteriosis could lead to inappropriate treatment with anti- tuberculosis drugs.

**Methods:** This cross-sectional, prospective study was conducted in patients with TB-like diseases attending six DOTs centres in Lagos, Nigeria, from May 2012 to October 2016. Participants' informed consent was obtained, structured questionnaires administered to obtain socio-demographic and co-morbid data. Sputum samples collected and processed for microscopy and culture using Lowenstein-Jensen medium with or without pyruvate and MGIT 960 liquid medium. Mycobacteria were identified using MPT64 immunochromatographic, biochemical and molecular methods. This study investigated the presence and prevalence of mycobacteriosis in the participants and assessed the risk factors for the mycobacterial infections.

**Results:** Of the 1,020 participants, 339 (33.2%) had mycobacteriosis of which 33 (9.7%) were caused by *Non-Tuberculosis Mycobacteria (NTM)* and 306 (90.3%) caused by *Mycobacterium tuberculosis complex (MTBC)*. Of the isolated 306 *MTBC*, 247 (80.7%) were *M. tuberculosis*, 28 (9.2%) were *M. africanum*, 23 (7.5%) were *M. bovis* while 8(2.6%) were *M. ulcerans* [P < 0.0005].

17 The 33 *NTM* showed 11 (33.3%), 20 (60.6%) had HIV, 8(24.2%) *M. fortuitum*, 2 (6.1%) *M. abscessus*, 2 (6.1%) *M. scrofulacium*, 6  
18 (18.2%) *M. kansasii*, 4 (12.1%) *M. megateriense* and 11 (33.3%) *Mycobacterium avium complex (MAC)*. Sequence analysis of the  
19 16s rRNA of the 11 *MAC* showed 3 (27.3%) *M. avium*, 5(45.5%) *M. intracellulare*, 2(18.2%) *M. colombiense* and 1(9.1%) *M. velneri*.  
20 *M. fortuitum* and *MAC* were significantly ( $P<0.05$ ) associated with HIV infection, while only *M. fortuitum* relate strongly with diabetes  
21 ( $P <0.05$ ).

22 **Conclusion:** The study showed mycobacteriosis caused by different species of *MTBC* and *NTM*. Relatively high mycobacteriosis  
23 were detected during dry season and were significantly associated with gender, age, HIV and diabetes.

24 **Key words:** Pulmonary mycobacteriosis, Mycobacteria, Risk factors, DOTs Centres, Lagos

25 **Abbreviation:** DOTs=Directly Observed Therapy Short Course

26

27

28 **Background:** Mycobacteriosis is defined as infection caused by different species of *Mycobacteria* including Non-Tuberculosis  
29 *Mycobacteria (NTM)* and *Mycobacterium Tuberculosis Complex* [2, 3]. *M. tuberculosis* is the commonest specie of *Mycobacteria*  
30 that causes pulmonary tuberculosis and it infects one third of the human world population and kills someone every 15 seconds [4].  
31 In Nigeria, tuberculosis (TB) is a major public health problem. It was declared a national emergency in June 2006 after which a  
32 plan for the control of TB in Nigeria was developed [6].

33 Despite expansion in case finding and DOTS coverage in the last 15 years in the country, the national case detection rate of 41% is  
34 still far below the 70% national and global target. This had been attributed to limited facilities for sputum culture and mycobacterial  
35 identification in the country coupled with poor access to health facilities and health seeking behaviour of TB suspects, particularly in  
36 the rural areas [3, 7]. NTM infections have been associated with the reactivation of latent TB and TB relapse or re-infection in  
37 previously cured patients [5]. They enhance the non-immunity effect of previous TB exposure [3, 11]. This is also among the  
38 challenges faced by the global TB elimination efforts [3].

39 The need for sputum culture and mycobacterial characterisation has become very important. This is to rule out mixed infections and  
40 Non-Tuberculous Mycobacteria (NTM) that are now on the increase in TB endemic developing countries and has outnumbered *M.*  
41 *tuberculosis* in incidence and prevalence in developed countries [3]. NTM which are environmental Mycobacteria found in water  
42 bodies, soil, animals and food products [8, 9] are increasingly being reported as causes of infections in immunocompetent and  
43 immunocompromised patients in Africa like in many developed countries of the world. Infections caused by the species include  
44 pulmonary infection, disseminated infection, meningitis, cervical lymphadenitis and pneumonitis [8]. The immunocompromised  
45 patients for which NTM has been documented to play a role in the pathogenesis, progression and severity of pulmonary infections  
46 include HIV seropositive patients, diabetes patients, patients with asthma, chronic obstructive pulmonary disease (COPD), nodular  
47 bronchiectasis and silicosis [8]. In Nigeria, a few studies have reported the occurrence of pulmonary infections due to NTM in

48 Lagos. There is no doubt that Nigeria require accurate characterisation of mycobacteria, rational use of first-line anti-TB regimen,  
49 improved knowledge of the role played by NTM in pulmonary and disseminated infections in Nigerian patients.

50 The objectives of the study were to investigate the presence and prevalence of Mycobacterial infections (mycobacteriosis) in  
51 patients suspected of pulmonary tuberculosis and to assess the risk factors responsible for the mycobacteriosis.

## 52 **Methods**

53 **Study sites.** This was a multicenter study covering randomly selected six health facilities with DOTs services in Lagos.

54 **Study design:** The study was a cross-sectional, prospective study on patients suspected of pulmonary mycobacterial infections  
55 (suspected TB patients) from May 2012 and October 2016.

56 **Ethical considerations:** Samples were collected from only participants who voluntarily gave informed consent and were able to  
57 submit 2 consecutive sputum samples. The study was also approved by Institutional review Board of the Nigerian Institute of  
58 Medical Research, Yaba, Lagos.

59 **Sample size:** Specimen collection: 1020 participants were enrolled and sputum samples collected from them. At enrolment, a pre-  
60 tested semi-structured questionnaire was administered per patient by a trained health worker to capture socio-demographic data  
61 such as age, gender, education, marital status and occupation. Information on tobacco smoking and alcohol intake habits as well  
62 as diagnosis or treatment to diabetes was also obtained. Each patient was then screened for HIV 1/II according to the national  
63 algorithm [6]. Two sputum samples-one on the spot (day 1), followed by the second samples (day 2) collected at early morning

64 were screened microscopically for presence of acid fast bacilli (AFB) and processed for culture as described by [14], MGIT  
65 manual, biochemical tests, immune-chromatographic (ICT) test and line probe molecular assay method.

#### 66 **Data Analyses**

67 Data obtained after questionnaire administration were double entered into Microsoft excel 2007 version and Epi Info version 6.1.  
68 They were validated for completeness and error before transfer to Statistical Package for Social Science (SPSS version 20) where  
69 analyses were done. Demographic variables such as age, sex, education, occupation, alcohol intake and clinical data such as  
70 presence of fever, cough, haemoptysis, night sweat, diabetes, and HIV were used as covariates and summarized as frequency and  
71 percentages (%) as well as mean  $\pm$  standard deviation (SD). Chi square ( $X^2$ ) of Fischer Exact (when frequency (n) < 5) test was  
72 used to evaluate the relationship between NTM occurrence and the covariates. Covariates with significant odd ratio (OR) and 95%  
73 confidence interval (95%CI) in the Logistic regression analysis were entered into multivariate Logistic regression model to  
74 independent predictors of NTM infections

#### 75 **Sputum Culture**

76 Sputum samples collected from patients with suspected pulmonary infections were decontaminated and digested with 2 volumes of  
77 N-acetyl-L-cystein 4% sodium hydroxide (NALC-NaOH) as described [15]. This was followed by centrifugation using refrigerated  
78 centrifuge at 3000 rpm for 15 min. The concentrated sediment was then used to prepare smear on a grease-free slide for ZN acid-  
79 fast staining. Sputum smear microscopy was performed on stained concentrated sputum smears prior to culture and on stained

80 culture isolates according to NTLCP guidelines [6]. The remaining sediment was then suspended in 1.5mL of phosphate buffered  
81 saline (PBS, pH 6.8) in a Falcon tube, covered and mixed by repeated inversion (2x). Aliquots (0.2mL each) of the homogenate  
82 were then used to inoculate Lowenstein-Jensen (LJ) slopes with and without sodium pyruvate as well as 0.5mL into Mycobacteria  
83 Growth Indicator Tube 960 [16] containing oleic acid-albumin-dextrose-catalase and polymyxin-amphotericin B-nalidixic acid and  
84 trimethoprim-azlocillin. All inoculated media were incubated at 37<sup>0</sup>C. Bactec MGIT 960 vials were introduced into the Bactec MGIT  
85 960 instrument as recommended by the manufacturer and tested either until they were found to be positive or for 6 weeks. The LJ  
86 medium with and without pyruvate slants were examined weekly for 8 weeks for the visible appearance of colonies. After  
87 confirmation of mycobacterial growth in a liquid or solid medium, the parallel media were read daily. On the day of detection, all  
88 positive liquid and solid media were examined by ZN staining to confirm the presence of AFB and sub-cultured onto Columbia agar  
89 with 5% sheep blood to check for contaminants. Samples that failed to show viability or turbidity at 8 weeks were regarded as  
90 negative for mycobacteria infections. *M. tuberculosis* on LJ was indicated as a slow growing ( $\geq 16$  days) pale cream rough dry  
91 colonies, including few ones that were granular and mucoid. Similar colonies on LJ sodium pyruvate medium were suspected to be  
92 those of *M. bovis*. Other fast (< 14 days) and slow growing yellow/orange pigmented colonies on LJ slant were taken as non-  
93 tuberculous mycobacteria (NTM).

94 **Identification of isolates:** Phenotypic methods such as Nitrate reduction Catalase Test, Growth on p-nitro benzoate (PNB)  
95 Medium, Tween 80 Hydrolysis test, Urease production test, MPT64 Immuno-chromatographic Assay and Hain's Line Probe Assay (

96 LPA) for common mycobacteria (CM) and atypical mycobacteria strains (AS) were used as described by Hains Line Probe  
97 technique.

98 MPT64 Immuno-Chromatographic Technique (ICT) was validated with reference mycobacterial and other bacterial strains.

99 The 16s rRNA gene of the 11 *M. avium* complex (MAC) was amplified from the DNA sample of each isolate by PCR using primers  
100 sp1 (5'-ACCTCCTTTCTAAGGAGCACC-3') and sp2 (5'-GATGCTCGCAACCACTATCCA-3') as previously reported [17] The  
101 sequencing reactions were performed in 3170 Applied Biosystem sequencer. These sequences were further compared with those  
102 deposited in GenBank, using the BLAST algorithm [18] Sequences that showed 98% identity at comparison were then considered  
103 as identified species as described in previous study [19].

104 **Results:** *M. tuberculosis* H37Rv used as control strain produced positive reaction with goat anti-MPT64 monoclonal antibody due  
105 to its secreted MPT64 antigen, other reference strains tested including *M. bovis* BCG Pasteur, *M. kansasii* and *E. coli* ATCC 25922  
106 gave negative reaction.

107 The mean age of the 1,020 participants was 35.3 years (standard error of mean (SEM): 2.7 yr) and 164 (16%) had tertiary  
108 education (table 1). The risk factors for MTBC infection were found to include gender [male 607 (59.5%) and female 413 (40.5%)]  
109 (AOR, 1.6, 95% confidence interval (CI): 1 – 2.6, P = 0.033), age 36 years and above (AOR, 1.6, 95% confidence interval (CI): 1 –  
110 2.6, P = 0.033). Of the 1020 participants, 382 (37. 5%) had bacterial pathogens. Non-mycobacteria (NMY) bacterial pathogens was  
111 43 out of 382 (11.3%) of all bacterial isolates while 339 (88.7%) were identified as Mycobacteria. Of this, 33 (9.7%) were NTM and

112 306 (90.3%) were MTBC (Figure 1). The analysis of the 33 NTM showed 8(24.2%) *M. fortuitum*, 11 (33.3%) *M. avium* complex, 2  
113 (6.1%) *M. abscesses*, 2 (6.1%) *M. scrofulacium*, 6 (18.2%) *M. kansasii* and 4 (12.1%) *M. megateriense* (figure 2) and out of  
114 which, 11 (33.3%) and 20 (60.6%) had HIV and represented previously treated cases. Among the 306 *Mycobacterium tuberculosis*  
115 complex (MTBC) isolated, 247 (80.7%) were *M. tuberculosis*, 28 (9.2%) were *M. africanum*, 23 (7.5%) were *M. bovis* while 8(2.6%)  
116 were *M. ulcerans* [P < 0.0005].

117 Sequence analysis of the amplified 16s rRNA of 11 *M. avium* complex (MAC) isolates revealed the identity of the isolates as 3  
118 (27.3%) *M. avium*, 5(45.5%) *M. intracellulare*, 2(18.2%) *M. colombiense* and 1(9.1%) *M. velneri*.

119 *M. fortuitum* and *M. avium* complex (MAC) were significantly (P<0.05) associated with HIV infection, while only *M. fortuitum* relate  
120 strongly with diabetes (P <0.05). On the whole, 62.5% of the HIV seropositive patients and 57.1% of those with diabetes had NTM  
121 infections (P<0.05). Among the species of NTM isolated, *M. fortuitum* and *M. avium* complex (MAC) were significantly (P<0.05)  
122 associated with HIV infection, while only *M. fortuitum* relate strongly with diabetes (P <0.05).

123 Of the 339 analysed, 115 (33.9%) engaged in trading, 134 (39.5%) were artisans and 90 (26.6%) were unemployed (table 2). The  
124 number of patients living with diabetes was 59 (17.4%), while 18 (5.3%) of the patients were HIV seropositive. Alcohol intake and  
125 tobacco smoking were documented in 74 (21.8%) and 81 (23.9%) patients respectively. Investigation of treatment history showed  
126 12.2% of the patients to represent previously treated TB cases. The percentage of MTBC patients with diabetes was 4.2%, while  
127 11.4% were previously treated TB cases. On the whole, variables such as age, education, occurrence of diabetes and HIV sero-



128 positivity were found to influence variation in the distribution of mycobacterial and non-mycobacterial infections associated with  
129 clinical symptoms of tuberculosis in the studied patients. Cough at a rate of 50 – 100% was the most frequent symptom reported  
130 (Table 3), while haemoptysis was the least in patients infected with MAC (18.2%) and *M. abscessus* (50%). The two patients  
131 infected with *M. scrofulaceum* reported weight loss and night sweat, On the whole, 90.9% of the NTM infected patients reported at  
132 least one of these symptoms. The months with high occurrence of NTM infections were found to be January (24.2%), February  
133 (12.1%) and November (15.2%) during the harmattan period. Isolates were not recovered in April, June and July at the peak of the  
134 rainy season (Figure 3).

135

## 136 DISCUSSION

137 More males (59.5%) than female (40.5%) were reported in this study. This finding is similar to the report of [20] who reported a  
138 male to female ratio of 1.3:1. This result also agreed with the data reported by [21, 22]. However, the report of this study was  
139 different from those of other studies [23] where more females were reported. The higher prevalence of TB among males than  
140 females in this report has also been reported by various researchers in South-East Nigeria where PTB prevalence of 35.5% among  
141 males and 26.9% among females in South-Eastern Nigeria had earlier reported [24]. PTB prevalence of 65% and 35% among  
142 males and females respectively in Lagos had been reported [25]. The higher prevalence of PTB among males could be as a result  
143 of frequent contact with infective droplets from contaminated environment since tuberculosis is acquired through in inhalation of

144 infectious droplets [23]. It has also been reported that males predominate among TB cases in most countries and that variation in  
145 the effect of gender in harbouring MDR-TB could be multifactorial which could include poor knowledge about TB and “male ego”  
146 that is common with males making them seek alternative local herbs in most cases [26]. The NTM species identified in this study  
147 include 8 (24.2%) *M. fortuitum*, 2 (6.1%) *M. abscessus*, 2 (6.1%) *M. scrofulacium*, 6 (18.2%) *M. kansasii*, 4 (12.1%) *M.*  
148 *megateriense* and 11 (33.3%) *Mycobacterium avium complex (MAC)*. Sequence analysis of the 16s rRNA of the 11 *MAC* showed 3  
149 (27.3%) *M. avium*, 5(45.5%) *M. intracellulare*, 2(18.2%) *M. colombiense* and 1(9.1%) *M. velneri*. The species of NTM identified in  
150 this study is similar to the Ibadan study where *M. chelonae*, *M. intracellulare* and *M. avium complex (M. intracellulare, M.*  
151 *scrofulaceum)* were also reported. This attest to the earlier report that in the setting of disease development, NTM share similar  
152 symptomatology with *M. tuberculosis* and that both groups of Mycobacteria can also not be differentiated by radiology, making  
153 accurate diagnosis of MTBC challenging at primary health care settings where culture and Mycobacterial identification facilities are  
154 lacking in the country[3, 11]. Unfortunately, there is no reporting system for NTM in many developing countries including Nigeria.  
155 This is partly due to poor awareness of the clinical relevance of NTM, their environmental preference and lack of evidence for  
156 person to person transmission of NTM in humans [11]. The presence of NTM in sputum specimen may lead to misdiagnosis of  
157 MTBC and inappropriate treatment with first–line anti-TB regimen (i.e. rifampicin, isoniazid, ethambutol and pyrazinamide) and  
158 second-line regimen, including injectable Aminoglycosides (e.g Amikacin or Kanamycin), Capreomycin and Fluoroquinolones [3,  
159 11, 12]. It has been reported that slow-growing NTM such as *Mycobacterium avium complex (MAC)* and *M. kansasii* require

160 macrolide-based regimen for case management and that NTMs have inherent resistance to the standard first-line and second-line  
161 anti TB drugs [5]. NTM infected patients are also at high risk of drug toxicities with these regimen, necessitating replacement of  
162 isoniazid with a fourth generation fluoroquinolone such as moxifloxacin [5]. The End TB Strategy, which Nigeria has also adopted,  
163 entails the reduction of TB cases by 80% and deaths by 90% by 2030 compared to 2015 and the subsequent elimination of TB by  
164 2050 [13].

165 Currently in few facilities in Nigeria, mycobacteria characterization is performed by culture of smear positive sputum samples on  
166 Lowenstein Jensen slope followed by biochemical tests to differentiate between mycobacteria species that constitute the MTBC  
167 complex. This study showed the need for a review of the TB treatment national guidelines which stipulates that most rapid  
168 mycobacteria positive sputum culture (of  $\leq 2$  weeks ) are often regarded as contaminants and affected patients were not eligible  
169 for DOTS [6].

170 Age groups of the participants with tuberculosis in this study range between 15-54years. This agreed with the report by other  
171 studies [21, 23 and 27]. The reason for this is because TB usually affects young people. This account for why TB disease is said to  
172 be a disease that affect economically productive age groups.

173 *The isolation of 90.3% MTBC* in this study was slightly higher than the 85% strains of MTB complex reported by other studies [28].  
174 The 9.7% mycobacteriosis due to NTM and the detection of 11 (33.3%) and 20 (60.6%) in HIV and previously treated cases  
175 implied that in HIV and in previously treated TB cases, AFB detected by sputum smear microscopy could be NTM. This could

176 inappropriately be diagnosed as MDRTB. Therefore, there is the need for culture and characterization of the mycobacterial isolates  
177 to rule out or confirm mycobacteriosis due to NTM in such cases. This finding also agreed with the report of [3, 9, 28] who reported  
178 similar findings in subjects with and without HIV and that *Non-Tuberculous Mycobacteria (NTM)* are involved in a range of diseases  
179 including pulmonary disease, hypersensitivity pneumonitis, cervical lymphadenitis, and disseminated infection and disseminated  
180 infection is generally associated with HIV infection. The prevalence of 9.7% of NTM in this study was however lower than 50% NTM  
181 reported by other Researchers among the HIV positive subjects [9]. It is also lower than the 11.6% reported by others in Lagos [25],  
182 the 13% reported in North Central part of Nigeria [26], the 15% prevalence reported [28] in subjects with and without HIV positivity  
183 and the 39% prevalence reported in Ibadan [3]. The prevalence of NTM in this study however agreed with the study of [30] who  
184 reported that NTM infections (mycobacteriosis due to NTM), vary between 4.1 to 47.0%. NTM infections have also been linked to  
185 harmattan dust exposure and to HIV co-infection; and have been reported to be a novel public health challenge which needs to be  
186 considered when planning for prevention and treatment of mycobacteriosis patients [28]. Education, occupation, smoking, alcohol  
187 intake, HIV and diabetes are confirmed to be associated with mycobacteriosis ( $p < 0.05$ ). These results agreed with the earlier one  
188 reported by other researchers [3, 9, 28]. This finding is very important in the need for better understanding of the efficacy of the first  
189 line anti-TB treatment regimens because the responses to the anti TB regimens by mycobacteriosis caused by *NTM* are known to  
190 vary from mycobacteriosis caused by *M. tuberculosis complex* [28]. Treatment of TB patients in most sub-Saharan African  
191 countries including Nigeria, is based solely on the results of microscopic smear positivity. Patients diagnosed using sputum smear

192 positive results alone, are indiscriminately placed on DOTS using first line anti-TB drugs in the current TB treatment strategy. The  
193 implication of the treatment strategy based on smear microscopy results alone is that *NTM* is inappropriately managed with first-line  
194 antituberculous drug thereby possibly worsening the patient's condition and raising the risk of drug resistance.  
195 The occurrence of 80.7% *M. tuberculosis*, 9.2% of *M. bovis*, 7.5% of *M. africanum* and 2.6%) of *M. ulcerans* of the total *MTBC* in  
196 this study agreed with the previous report that most sputum smear positive patients are caused mainly by *M. tuberculosis*[9]. The  
197 results are also similar to 94.4% *Mycobacterium tuberculosis*, 5.3% had *Mycobacterium africanum* and 0.3% had *Mycobacterium*  
198 *bovis*[29]. The prevalence of 7.5% *M. bovis* reported in this study was higher than 0.3% reported by others [29]. This may be due to  
199 the fact that the study site in this study is from Lagos, in south western part of Nigeria, where the population and consumption of  
200 dairy products is higher unlike the study conducted in Zaria- North western part of Nigeria [29]. This also implied that *M. bovis* is still  
201 a common cause of pulmonary tuberculosis in the study area. The production of dairy milk and cheese from cattle locally, could be  
202 responsible possibly due to non-pasteurization of such milk. This finding is however, contrary to earlier report that *M. bovis* was  
203 once a common cause of tuberculosis, but since the introduction of pasteurized milk, it has been largely eliminated as a public  
204 health problem in developed countries [29].

205

206

207 **Conclusions and recommendations**

208 More males than female had mycobacteriosis in this study. It was also established from this study that mycobacteriosis can be  
209 caused by *Mycobacterium tuberculosis complex (MTBC)* and or species of *Non Tuberculosis Mycobacteria (NTM)*.

210 Four species of *MTBC* were detected in this study. *M. tuberculosis* was the most prevalent species (80.3%) in the study area  
211 followed by *M. bovis* (7.5%), *M. africanum* (9.2%); and *M ulcerans* (2.6%). Also 9.7% of the mycobacteria were *Non-Tuberculosis*  
212 *Mycobacteria (NTM)* consisting of *M. scrofulacium*, *M.kansasii*, *M.megateriense*, *M abscessus*, *M. fortuitum* and *M. avium complex*  
213 (*M. avium*, *M. intracellulare*, *M. colombiense*, *M. velneri*). *M. fortuitum* and *M. avium complex (MAC)* were significantly ( $P<0.05$ )  
214 associated with HIV infection, while only *M. fortuitum* relate strongly with diabetes ( $P <0.05$ ). This study revealed 9.7% of *NTM*  
215 mycobacteriosis associated with dry season, HIV and diabetes. The usual TB case detection by microscopy only for DOTs  
216 programme could be misleading as exaggerated data on tuberculosis using microscopy alone will be over-diagnosing pulmonary  
217 infections caused by *MTBC*, possible false impression of MDRTB and possible inappropriate anti-TB treatment regimen. All sputum  
218 smear positive suspected cases of pulmonary mycobacteriosis should be referred for culture, identification and drug susceptibility  
219 testing. Capacities for this must be strengthened. Large scale, multi-centre, nation-wide study of mycobacteriosis is also  
220 recommended.

#### 221 **What is already known on this topic**

- 222 • That mycobacteriosis is a form of opportunistic infection especially in immunocompromised
- 223 • That In dry season, respiratory illnesses are common and these include mycobacteriosis

224 **What this study adds**

225• Not all sputum smear positive cases should be placed on the usual anti TB regimen. It could be a case of mycobacteriosis caused  
226 by NTM and these require special drugs different from the usual first-line anti TB regimen

227• Six (6) different species of NTMs were identified in this study

228• Not all sputum smear cases are MDRTB. It may be a case of re-infection with NTMs

229 **Acknowledgements:** The Authors acknowledge the support provided by the Management of Nigerian Institute of Medical  
230 Research, Yaba Lagos, Nigeria for the use of their facilities and for providing the control organisms used for the study.

231 **Competing interests:** There was no competing interests by the authors in this study.

232

233 **Authors' contributions: TY Raheem:** Designed the proposal, procured the materials and the reagent used for the study, involved  
234 in collection of the samples, processing of the samples, data entry and analysis, wrote the manuscript and submitted it for  
235 publication.

236 **Iwalokun BA:** Supervised the study, involved in the molecular analysis, did data analysis and reviewed the manuscript.

237 **Oluwadun A:** Co-supervised the study and reviewed the manuscript.

238 **Adesesan O A:** Involved in the sputum culture procedures, identification of the isolated mycobacteria and reviewed the manuscript

239 **Tochukwu N:** Involved in the sputum culture procedures and identification of the isolated mycobacteria.

240 **Nshiogu M:** Involved in the preparation of the reagent used for the analysis and in the phenotypic identification of the isolated  
241 mycobacteria.

242

243

244


245

246

247

248

249



250

Fig 1: Distribution of the species of MTBC isolated from the participants [p< 0.001]



Table 1: Distribution of aetiologies of suspected pulmonary tuberculosis according to socio-demographic, behavioral and environmental characteristics of the patients.

Characteristics	Total isolates N = 339 N (%)	MTB-C N = 306 n (%)	NTM N =33 n (%)	Non-Mycobacterial infection (NMY) N = 43 (%)	P-value ( $\chi^2$ or t-test)
<b>Age group, yr, n (%)</b>					
18 – 35	154(45.4)	140(45.7)	11	34 (79.1)	25.9; < 0.0001
≥36	185(54.3)	166(54.3)	22 (33.3)	9 (20.9)	
<b>Mean age, yr (mean ± SEM)</b>	34.3+1.5	36.1+1.2	32.5 + 0.4	33.4+ 1.4	
<b>Gender, n (%)</b>					
Male	205(60.5)	188(61.4)	20	25 (58.1)	0.41; 0.81
Female	134(39.5)	118(38.6)	13(39.4)	18 (41.9)	
<b>Education, n (%)</b>					
Primary	122(35.9)	106(34.6)	10	28 (65.1)	27.8; <0.0001
Secondary	167(49.3)	165(53.9)	15	9 (20.9)	
Tertiary	50(14.8)	35(11.4)	8(24.2)	6 (14)	
<b>Occupation, n (%)</b>					
Trading	92(27.1)	87(28.4)	15	11 (25.6)	28.7; 0.00041
Artisan	103(30.3)	86(28.1)	15	7 (16.3)	
Civil servants	39(11.5)	38(12.4)	8(24.2)	9 (20.9)	
Private sector worker	31 (9.1)	28 (9.2)	9 (27.3)	10 (23.3)	
Unemployed	74(21.8)	67(21.9)	13	6 (14)	

<b>Diabetic, n(%)</b>	45(13.3)	76(24.8)	(39.4)	8 (18.6)	18.7; < 0.0001
Yes	294(86.7)	230(75.2)	3(9.1)	35 (81.4)	
No			2 (6.1)	6 (18.2)	
<b>HIV seropositive, n (%)</b>	37 (10.9)	254(83.0)		0 (0)	7.6; 0.02
Yes	302(89.1)	52 (17.0)	1 (3.0)	43 (100)	
No			32(97.0)		
<b>Alcohol intake (%)</b>	56 (16.5)	265(86.6)		5 (11.6)	12.1; 0.002
Yes	283(83.5)	41(13.4)		38 (88.4)	
No			3 (9.1)		
			30		
			(90.9)		
<b>Smoking, n (%)</b>	61 (18)	50 (16.3)		16 (37.2)	16.4; 0.0003
Yes	278 (82)	256(83.7)		27 (62.8)	
No			7(21.2)		
			26		
			(78.8)		
<b>Treatment history, n(%)</b>	297(87.6)	64(20.9)		43 (100)	10; 0.007
Newly diagnosed	42(12.4)	242(79.1)		0 (0)	
Previously treated			3 (9.1)		
			30		
			(90.9)		
			27		
			(81.8)		
			6 (18.2)		

253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273

--	--	--	--	--	--

MTB-C= Mycobacterium tuberculosis complex

NTM=Non tuberculosis mycobacteria, NMY=Non Mycobacteria.

UNDER PEER REVIEW

274 **Table 2: Distribution of Non-tuberculous mycobacteria species among participants with HIV and Diabetes**

275

NTM species	HIV positive (Total = 40), n (%)	P-value	Diabetes positive (Total = 14), n (%)	P-value
<i>M. fortuitum</i> ,	5 (12.5)	<b>0.02</b>	3 (21.4)	<b>0.02</b>
MAC	9 (22.5)	<b>0.00001</b>	2 (14.3)	0.34
<i>M. abcessus</i>	2 (5)	0.08	0 (0)	0.33
<i>M. scrofulaceum</i>	1 (2.5)	0.53	1 (7.1)	0.38
<i>M. kansasii</i>	4 (10)	0.08	2 (14.3)	0.13
<i>M. mageritense</i>	4 (10)	0.08	0 (0)	0.67
<i>Total</i>	25 (62.5)	<b>&lt;0.000001</b>	8 (57.1)	<b>0.0001</b>

276

277 There is significant association between *NTM* infections and HIV and Diabete.




Fig 2: Distribution of Species of NTM isolated from the participants

**Table 3: Distribution of the NTM species by symptoms reported by the infected patients**

NTM species	No. of isolates	Cough, N (%)	Night sweat, n (%)	Weight loss, n (%)	Haemoptysis, n (%)	Chest pain, n (%)	Fever, n (%)	Any symptom, n (%)
<i>M. fortuitum</i> , MAC	8 11	7 (87.5)	3 (37.5)	2 (25)	0 (0)	5 (62.5)	2 (25)	8 (100)
<i>M. abscessus</i> <i>M.</i> <i>scrofulaceum</i>	2 2 6	8 (72.7) 2 (100)	0 (0) 2 (100) 4 (66.7)	1 (50) 2 (100) 2 (33.3)	1 (50) 0 (0) 0 (0)	2 (100) 0 (0) 2 (33.3)	2 (100) 2 (100) 1 (16.7)	2 (100) 2 (100) 5 (83.3)
<i>M. kansasii</i> <i>M.</i> <i>megateriense</i>	4 33 2	1 (50) 4(66.7) 2 (50)	3 (75) 18(54.5) )	1 (25) 15 (45.5)	0 (0) 3 (9.1)	0 (0) 12 (36.4)	1 (25) 12 (36.4)	4 (100) 30 (90.9)
<i>Total</i>		22(66.7) )						




Figure 3: Monthly occurrence of *NTM* infection among the patients with suspected tuberculosis

## References

1. Wolters Kluwer, Lippincott Williams and Wilkins. Stedman's Medical Dictionary, 2012. Publisher Julie K Stegman. ISBN 978-1-60831-692-2).
2. Palomino JC, Leão SC and Ritacco V in *Tuberculosis: From basic science to patient care [www.TuberculosisTextbook.com](http://www.TuberculosisTextbook.com)* , 2007., 406-408.
3. Cadmus Simeon Idowu, Bassirou Diarra, Brehima raore, Mamoudou Maiga, Sophia Siddiqui, Anatole Tounkara, Olutayo Falodun, Wole Lawal, Isaac Folorunso Adewole, Rob Murphy, Dick van Soolingen and Babafemi Nontuberculous Mycobacteria Isolated from Tuberculosis Suspects in Ibadan, Nigeria *Journal of Pathogens*. Taiwo 2016., Article ID 6547363, 5 pages <http://dx.doi.org/10.1155/2016/6547363>
4. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S: High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. *PLoS Biology*, 2008., 6(12): e311. doi:10.1371/journal.pbio.0060311
5. World Health Organization: Global tuberculosis report pg 1-50; WHO/HTM/TB.22. 2015
6. *National Tuberculosis and Leprosy Control Programme* publication: Modules for Training General Health care Workers on TB Control 4<sup>th</sup> Edition: 37-98. 2011.
7. Lana Dinic, Patrick Akande, Emmanuel Oni Idigbe, Agatha Ani, Dan Onwujekwe, Oche Agbaji, Maxwell Akanbi, Rita Nwosu, Bukola Adeniyi, Maureen Wahab, Chindak Lekuk, Chioma Kunle-Ope, Nkiru Nwokoye, and Phyllis Kanki Genetic Determinants of Drug-Resistant Tuberculosis among HIV-



Infected Patients in Nigerian *Journal of Clinical Microbiology*. 2012., September vol. **50** (9), 2905-2909.

8. Griffith Chris, Pat Sturdy, Penny Brewin, Graham Bothamley, Sandra Eldridge, Adrian Martineau, Meg MacDonald, Jean Ramsay, Suresh Tibrewal, Sue Levi, Ali Zumla, Gene Feder: Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial. *Lancet*; 2007., **369**: 1528–1534
9. Pokam, Benjamin T and Asuquo, Anne E: Acid-Fast Bacilli Other than Mycobacteria in Tuberculosis Patients Receiving Directly Observed Therapy Short Course in Cross River State, Nigeria. *Tuberculosis Research and Treatment* 2012., Volume, Article ID 301056, 4 pages doi:10.1155/2012/301056.
10. Idigbe EO, Anyiwo CE, Onwujekwe DI. Human pulmonary infections with bovine and atypical mycobacteria in Lagos, Nigeria. *Journal of Tropical Medicine and Hygiene*. 1986., **89**:143-148.
11. Van Halsema CL, Chihota VN, Gey van Pittius NC, Fielding KL, Lewis JJ, van Helden PD, Churchyard GJ, Grant AD: Clinical Relevance of Nontuberculosis Mycobacteria Isolated from Sputum in a Gold Mining Workforce in South Africa: An Observational, Clinical Study. *Biomedical Research International*. 2015., Epub.10.1155/2015/959107
12. National Tuberculosis and Leprosy Control Programme: The National Strategic Plan for Tuberculosis Control. Towards Universal Access to Prevention, Diagnosis and Treatment 60-75. 2014.

13. Kent, P.T. and Kubica, G.P. Public Health Mycobacteriology. A guide for the level III laboratory. US Department of Health and Human Services, Centre for Disease control, Atlanta. 50-88. 1985.
14. Scott, H. M., & Flynn, J. L. *Mycobacterium tuberculosis* in Chemokine Receptor 2-Deficient Mice: Influence of Dose on Disease Progression. *Infection and Immunity*, 2002., **70**: 5946–5954.
15. SH Siddiqi: MGIT 960™ Procedure Manual-Foundation for Innovative New Diagnostics pges 9-16. 2006.
16. Roth A, Fisher M, Hamid E, Michalke S, Ludwig W and Mauch H. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. *Journal of Clinical Microbiology* 1998., **36**:139-147.
17. NCBI: [www.blast.ncbi.nlm.nih.gov/Blast.cgi](http://www.blast.ncbi.nlm.nih.gov/Blast.cgi).
18. Turenne, Christine Y; Lorelee Tschetter, Joyce Wolfe and Amin Kabani: Necessity of Quality-Controlled 16S rRNA Gene Sequence Databases: Identifying Non-Tuberculous Mycobacterium Species. *Journal of Clinical Microbiology* 2001., **39**(10), 3637–3648.
19. Adejumo OA, Daniel OJ, Abdur-Razzaq HA, Shogbamimo YO, Femi-Adebayo T, Adepoju VA, Adebayo BI and Sodipo OO: Trend of tuberculosis case notification and treatment outcome in Lagos State, Nigeria: a 5-year retrospective study. *Transactions Royal Society of Tropical Medicine and Hygiene*. 2017., **111** (7):300-307.
20. WHO report: Global tuberculosis control (WHO/HTM/TB/.16 ISBN 978 92 4 156438 0) pg 54-55. 2011.

21. Okodua M., Ihongbe J., Esumeh F. Pulmonary Tuberculosis and Resistance Pattern to first line Anti-tuberculosis Drugs in a City of Western Nigeria. *International Journal of Basic, Applied and Innovative Research*. 2012., **1**(2):48 – 56.
22. Raheem T.Y., Onubogu CC, Igbasi UT, Nwokoye N, Tochukwu N, Kunle-Ope C, Ejezie C, Omoloye R, Adesesan A A, Okoye RN, Ajayi F, Nureni A, Oba AO and Onwujekwe D. Observed Tuberculosis Treatment Outcomes among Patients with Different Human Immunodeficiency Virus Sero-status at a Health Facility in Lagos, Nigeria; *Journal of Medical Laboratory Science*. 2013., **22** (1) 3-7.
23. Itah, A.Y. and Udofia, S.M: Epidemiology and Endemicity of pulmonary tuberculosis (PTB) in South-Eastern Nigeria. *South Asian Journal of Tropical Medicine. Public Health*. 2005., **36**(2):317-323.
24. WHO report. Global tuberculosis control (WHO/HTM/TB/16 ISBN 978 92 4 156438 0) pg 54-55. 2011.
25. Idigbe E.O., John E.K.O., Duque R. and Annam O.: Resistance to anti tuberculosis drugs in Lagos. *Journal of Tropical. Medicine and Hygiene (London)*. 1992., **95**: 186-191.
26. Aliyu Gambo, Samer S. El-Kamary, Alash'le Abimiku, Nicholas Ezati, Iwakun Mosunmola, Laura Hungerford, Clayton Brown, Kathleen J. Tracy, Joshua Obasanya and William Blattner: Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria. *Tuberculosis Research and Treatment* Article ID 650561, 9 pages. 2013.

27. Mohammed, Javad Nasiri, Hossein Dabiri, Davood Darban-Sarokhalil, Abdolrazagh Hashemi Shahraki: Prevalence of Non-Tuberculosis Mycobacterial Infections among Tuberculosis Suspects in Iran: Systematic Review and Meta-Analysis. *Plos One*. 2015., Published: June 8, <https://doi.org/10.1371/journal.pone.0129073>

28. Kendall BA, Winthrop KL: Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. *Seminar on Respiratory Critical Care Medicine* .2013., **34**:87-94.

29. Thoen C, Lobue P, de Kantor I: The importance of *M. bovis* as a zoonosis. *Veterinary Microbiology*; 2006., *112* (2-4):339-345.